Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs.

Area of Science:

• Hematology
• Gene Therapy
• Platelet Biology

Background:

• Inherited platelet defects, like Glanzmann thrombasthenia (GT), cause bleeding disorders due to issues with the integrin αIIbβ3 receptor.
• Current treatments like transfusions are often ineffective due to antibody formation against αIIbβ3, and bone marrow transplants carry significant risks.

Purpose of the Study:

• To investigate hematopoietic stem cell gene transfer as a therapeutic strategy for Glanzmann thrombasthenia (GT) using a canine model.
• To assess the efficacy of gene therapy in restoring platelet function and improving hemostasis in a preclinical setting.

Main Methods:

• Utilized a canine model of Glanzmann thrombasthenia (GT) for hematopoietic stem cell gene transfer.
• Employed a mild pretransplant conditioning regimen and in vivo drug selection to enhance engraftment of autologously transplanted cells.
• Evaluated platelet function, including αIIbβ3 receptor expression, fibrinogen binding, aggregation, and clot retraction.

Main Results:

• Gene transfer resulted in the expression of approximately 5,000 αIIbβ3 receptors on 10% of platelets, enabling adhesion, aggregation, and clot retraction.
• Significant improvements in hemostatic function were observed, with up to 135-fold reduction in blood loss and buccal bleeding times decreasing to 4 minutes for up to 5 years.
• One dog developed an antibody response to αIIbβ3, which was effectively managed with transient immune suppression.

Conclusions:

• Hematopoietic stem cell gene transfer is a viable strategy for treating inherited platelet defects like Glanzmann thrombasthenia (GT).
• This approach demonstrates potential for restoring platelet function and significantly improving hemostasis, offering a promising alternative to existing therapies.